Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 7/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
| ▸ | AGT | P01019 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310910 | 0.95 | AGT (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL9613559 | 0.94 | AGTR1 (0.58) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL14855717 | 0.94 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7886503 | 0.94 | AGTR1 (0.51) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7301890 | 0.94 | AGTR1 (0.51) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7297174 | 0.93 | AGTR1 (0.56) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL29205120 | 0.93 | AGTR1 (0.52) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL8086343 | 0.93 | AGTR1 (0.51) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1308518 | 0.92 | AGTR1 (0.65) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL7878554 | 0.92 | AGTR1 (0.49) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104650048-B | Purification method of olmesartan medoxomil condensation compound | 浙江华海药业股份有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-111253375-A | Preparation and purification method of key intermediate of olmesartan medoxomil | 山东新华制药股份有限公司 | 2020-06-09 | — | — | CN | claimed |
| WO-2012069025-A1 | (5-METHYL-2-OXO-1,3-DIOXOL-4-YLMETHYL)-4-(1-HYDROXY-1-METHYL-PROPYL)-2-PROPYL-1-[2'- (1H-TETRAZOL-5-YL)BIPHENYL-4-YL-METHYL]IMIDAZOLE-5-CARBOXYLATE AS AN IMPURITY OF OLMESARTAN MEDOXOMIL AND A METHOD OF ITS PREPARATION | ZENTIVA, K.S. (CZ) | 2012-05-31 | — | — | WO | claimed |
| US-8048904-B2 | Process for the preparation of olmesartan medoxomil | MATRIX LABORATORIES LTD. (IN) | 2011-11-01 | — | — | US | claimed |
| EP-2334668-A1 | PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2011-06-22 | — | — | EP | claimed |
| WO-2010026255-A1 | PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2010-03-11 | — | — | WO | claimed |
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | claimed |
| CN-110396084-B | Method for preparing high-purity trityl olmesartan medoxomil | 连云港润众制药有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-104650048-B | Purification method of olmesartan medoxomil condensation compound | 浙江华海药业股份有限公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111253375-A | Preparation and purification method of key intermediate of olmesartan medoxomil | 山东新华制药股份有限公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-2902385-B1 | DEPROTECTION METHOD FOR TETRAZOLE COMPOUND | API CORP (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-9624181-B2 | Method for producing biaryl compound | API CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9527821-B2 | Deprotection method for tetrazole compound | API CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| WO-2009019304-A1 | A PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | LEK PHARMACEUTICALS D.D. (SI) | 2009-02-12 | — | — | WO | disclosed |
| WO-2007148344-A3 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX LAB LTD (IN) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007148344-A2 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX LABORATORIES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MED1, TET1, AGTR1 | AGTR1 3/4885AGTR2 5/4885ABCC3 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.